CD8A and neoplasm: Another study demonstrated that lenalidomide enhances the anti-tumor capacity of CAR-T cells by promoting CD8 + CAR-T cell differentiation into CD8 + central memory T cells and helper T cells [48], modulating the tumor microenvironment for enhanced CAR-T cell infiltration and delaying CAR-T cell depletion.